Myrtle Beach, North Carolina Clinical Trials

A listing of Myrtle Beach, North Carolina clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

The purpose of this study is to evaluate the objective response rate (complete response [CR]+ partial response [PR]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.

dose regimen
renal function
erdafitinib
measurable disease
adjuvant chemotherapy
Carolina Urologic Research Center
 (6.7 away) Contact site
  • 40 views
  • 28 Jul, 2021
  • +152 other locations
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemotherapy or new hormonal agents (NHAs) at metastatic castration-resistant prostate …

progressive disease
gonadotropin releasing hormone
androgen
abiraterone
adenocarcinoma
Research Site
 (6.7 away) Contact site
  • 200 views
  • 23 Jul, 2021
  • +194 other locations
Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus-Calmette-Guerin

To evaluate the activity of intravesical (IVE) administration of CG0070 in patients with tissue pathology confirmed non-muscular invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease, with either carcinoma in situ with or without Ta/T1 disease

Carolina Urologic Research Center
 (6.7 away) Contact site
  • 0 views
  • 04 Aug, 2021
  • +32 other locations
Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer

CREST: Combination of sasanlimab and alternative BCG Regimens to Evaluate outcomes with Subcutaneous anti-PD-1 Treatment Phase 3 Design with 3 study Arms (A, B and C). Arms A and B consists of two study drugs, PF-06801591 plus BCG. Arm C consists of one study drug, BCG. The study is designed …

Carolina Urologic Research Center
 (6.7 away) Contact site
  • 10 views
  • 04 Aug, 2021
  • +218 other locations
A Study of FT-7051 in Men With MCRPC

This is a Phase 1, open-label study that will evaluate the safety and tolerability of FT-7051 and determine the recommended Phase 2 dose (RP2D) as well as pharmacokinetics (PK), preliminary anti-tumor activity, and pharmacodynamics (PD) of FT-7051 in men with metastatic castration-resistant prostate cancer who have progressed despite prior therapy …

Carolina Urologic Research Center
 (6.7 away) Contact site
  • 0 views
  • 25 Jul, 2021
  • +7 other locations
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations.

Research Site
 (6.7 away) Contact site
  • 0 views
  • 26 Jul, 2021
  • +22 other locations
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer

This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter …

intravesical bcg
bacillus calmette-guerin
chemoradiation
intravesical chemotherapy
metastatic cancer
Carolina Urologic Research Center
 (6.6 away) Contact site
  • 284 views
  • 23 Jul, 2021
  • +92 other locations
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib combination therapies (Combinations 1 and 2) and b) to determine the relative bioavailability of niraparib and abiraterone acetate (AA) in combination (Combination 3) in participants …

Carolina Urologic Research Center
 (6.7 away) Contact site
  • 506 views
  • 26 Jul, 2021
  • +83 other locations
Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

The purpose of this study is to evaluate the effectiveness of ProstAtak immunotherapy in combination with radiation therapy for patients with intermediate-high risk localized prostate cancer. ProstAtak kills tumor cells and stimulates a cancer vaccine effect. Killing tumor cells in an immune stimulatory environment induces the body's immune system to …

external beam radiation therapy
androgens
antiandrogen therapy
tumor cells
cancer vaccine
Carolina Urologic Research Center, LLC
 (6.6 away) Contact site
  • 1420 views
  • 04 Aug, 2021
  • +78 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is either persistent or recurrent following adequate BCG induction (Cohort A), or that is nave to BCG treatment (Cohort B). The primary hypothesis …

Carolina Urologic Research Center ( Site 1085)
 (6.7 away) Contact site
  • 108 views
  • 04 Aug, 2021
  • +138 other locations